Expert Perspectives: Sequencing Approaches with CAR-T and Bispecifics in R/R MM
The expert panel shares clinical insights on sequencing CAR T-cell therapies and bispecific antibodies for patients with relapsed/refractory multiple myeloma.
Treatment Strategies with Elranatamab in R/R MM: Updates from the MagnetisMM Trials
Naresh Bumma, MD, and Hans Lee, MD, recap recent updates on the MagnetisMM-30 an MagnetisMM-32 studies investigating elranatamab, a BCMA-directed bispecific antibody.
Key Takeaways on Recent Data from PERSEUS
Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.
Identifying Optimal Doses and Supporting Data for IORT in Pancreatic Cancer
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Recent findings from BESPOKE
Key opinion leaders analyze recent findings from the BESPOKE study.
Clinical study of ctDNA-based MRD detection and INTERCEPT program update
The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).
Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis
Renal cell carcinoma specialists provide a comprehensive overview of chromophobe renal cell carcinoma (ChRCC), including its definition, background, and distinctive characteristics.
PAPMET Phase II Trial Advances Cancer Treatment Landscape
Key opinion leaders examine the Phase II PAPMET clinical trial, focusing on its design and progression-free survival outcomes.
Collaborative Education for CAR T-Cell Therapy
The panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.
Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM
The panel concludes by offering key takeaways on the treatment of patients with relapsed/refractory multiple myeloma who receive CAR T-cell therapy.
Epcoritamab Approval in R/R Follicular Lymphoma May Offer Ease of Use
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Treating Patients with SCLC with Driver Mutations
The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.
Adverse Event Management Practices in SCLC
Eric Singhi, MD, joins the Oncology Brothers to discuss adverse event management practices for patients with small cell lung cancer.
Treatment Practices for Extended-Stage Small Cell Lung Cancer
Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.
Incorporating PCI Following ADRIATIC Study
Following recent data from the ADRIATIC study, the Oncology Brothers and Eric Singhi, MD, discuss the role of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer.
Treatment Algorithm for Limited-Stage Small Cell Lung Cancer
Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with limited-stage small cell lung cancer (SCLC), highlighting the ADRIATIC study.
Key Findings from the INTERCEPT Study
GI medical oncologists review recent findings from the INTERCEPT study evaluating the prognostic performance of circulating tumor DNA in clinical practice.
The Role of ctDNA as a Biomarker in Colorectal Cancer
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, discuss the role of circulating tumor DNA (ctDNA) as a biomarker in colorectal cancer and provide clinical insights on screening modalities.
Naval Daver, MD on Phase 1/2 Trial of DSP-5336 in R/R Acute Leukemia
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
Tanya B. Dorff, MD, on Phase 1 Trial of CAR T-Cell Therapy in mCRPC
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "4 KOLs are featured in this panel.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "2 KOLs are featured in this series")
